SCHEMBL31146209

SCHEMBL31146209

COC(=O)C(C)c1c(C2CC2)c2c(OC)nccc2[nH]c1=O

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 5/20 0.35
▸ IDO1 P14902 6/20 0.34
▸ NR1I2 O75469 1/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ TLR8 Q9NR97 3/20 0.32
▸ TLR7 Q9NYK1 3/20 0.32
▸ CYP19A1 P11511 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ TLR9 Q9NR96 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ IDH1 O75874 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31145941 0.90 IDO1 (0.35) LRRK2IDO1NR1I2CYP2C8CYP2C9
SCHEMBL31146216 0.84 KDM5A (0.35) LRRK2KDM4EALDH1A1SMN1; SMN2IDH1
SCHEMBL31145974 0.79 PDE2A (0.36) IDO1IDH1
SCHEMBL31146155 0.79 PDE2A (0.36) IDO1IDH1
SCHEMBL31145856 0.76 CXCR2 (0.33) LRRK2IDH1
SCHEMBL31146055 0.76 PDE3B (0.38) KDM4EALDH1A1TSHRSMN1; SMN2IDH1
SCHEMBL31145950 0.75 BRD4 (0.36) ALDH1A1SMN1; SMN2IDH1
SCHEMBL31145984 0.74 LRRK2 (0.35) LRRK2CYP2C19KDM4EALDH1A1SMN1; SMN2
SCHEMBL31145938 0.66 KDM5A (0.44) KDM4EALDH1A1
SCHEMBL31145955 0.61 PDE3B (0.41) CYP2C19KDM4EALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A LRRK2 2957/4885IDO1 1545/4885NR1I2 271/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A LRRK2 2957/4885IDO1 1545/4885NR1I2 271/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 LRRK2 3161/4885IDO1 2309/4885NR1I2 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback